ORIGINAL ARTICLE LIVER TRANSPLANTATION 20: , Additional Supporting Information may be found in the online version of this article.
|
|
- Ginger Fields
- 5 years ago
- Views:
Transcription
1 LIVER TRANSPLANTATION 20: , 2014 ORIGINAL ARTICLE Statin Therapy Is Associated With the Development of New-Onset Diabetes After Transplantation in Liver Recipients With High Fasting Plasma Glucose Levels Yongin Cho, 1 * Min Jung Lee, 5 * Eun Yeong Choe, 1 Chang Hee Jung, 5 Dong Jin Joo, 2 Myoung Soo Kim, 2 Bong Soo Cha, 1,3,4 Joong-Yeol Park, 5 and Eun Seok Kang 1,3,4 1 Division of Endocrinology and Metabolism, Department of Internal Medicine, 2 Department of Transplantation, 3 Brain Korea 21 Project for Medical Science, and 4 Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea; and 5 Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea New-onset diabetes after transplantation (NODAT) and dyslipidemia are important metabolic complications after liver transplantation (LT) that can adversely affect both allograft and patient survival. Statins are used as first-line therapies for dyslipidemia because of their effectiveness and safety profile. However, it has recently been reported that statin therapy is associated with new-onset diabetes in the nontransplant population. The aim of this study was to investigate the association between statin therapy and the development of NODAT in LT recipients. Three hundred sixty-four LT recipients who underwent transplantation between the ages of 20 and 75 years without a previous history of diabetes were enrolled in this study. We evaluated the incidence of NODAT with respect to statin use as well as other risk factors. The incidence of NODAT was significantly higher in the statin group (31.7%) versus the control group (17.6%, P ). The mean follow-up period was months for the statin group and months for the control group (P ). Statin use was significantly associated with NODAT development after adjustments for other risk factors [hazard ratio (HR) , 95% confidence interval (CI) , P ]. Impaired fasting glucose before transplantation was also a risk factor for NODAT devel- Additional Supporting Information may be found in the online version of this article. Abbreviations: BMI, body mass index; CI, confidence interval; FPG, fasting plasma glucose; HR, hazard ratio; IFG, impaired fasting glycemia; LT, liver transplantation; NODAT, new-onset diabetes after transplantation. Yongin Cho and Min Jung Lee participated in the design and performance of the study, the data collection and analysis, the data interpretation, and the writing of the manuscript. Eun Yeong Choe participated in the design and performance of the study, the data analysis, and the data interpretation. Dong Jin Joo participated in the data collection. Myoung Soo Kim, Bong Soo Cha, and Joong-Yeol Park contributed to the discussion. Chang Hee Jung participated in the design and performance of the study and the data collection and analysis. Eun Seok Kang participated in the design and performance of the study, the data collection and analysis, the data interpretation, and the writing of the manuscript. All the authors declare that there is no duality of interest associated with this article. This work was financially supported by the Kiturami Faculty Research Assistance Program of the Yonsei University College of Medicine ( ) and by a National Research Foundation grant funded by the Korean Ministry of Education, Science, and Technology through the Basic Research Promotion Fund (NRF E0008 and NRF ). *These authors contributed equally to this work. Address reprint requests to Joong-Yeol Park, M.D., Ph.D., Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro, 43-Gil, Songpa-Gu, Seoul , Korea. Telephone: ; FAX: ; jypark@amc.seoul.kr Address reprint requests to Eun Seok Kang, M.D., Ph.D., Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-Ro, Seodaemun-Ku, Seoul , Korea. Telephone: ; FAX: ; edgo@yuhs.ac DOI /lt View this article online at wileyonlinelibrary.com. LIVER TRANSPLANTATION.DOI /lt. Published on behalf of the American Association for the Study of Liver Diseases VC 2014 American Association for the Study of Liver Diseases.
2 558 CHO ET AL. LIVER TRANSPLANTATION, May 2014 opment (HR , 95% CI , P ). There were no significant differences in age, body mass index, cumulative corticosteroid dose, or fasting plasma glucose (FPG) levels between the groups. Patients with high FPG levels were more likely to develop NODAT when they were placed on statins after LT (P ). In conclusion, statin treatment could contribute to the development of NODAT in LT recipients, especially if they have high baseline FPG levels. Liver Transpl 20: , VC 2014 AASLD. Received August 12, 2013; accepted January 19, In recent years, liver transplantation (LT) has become a widely accepted treatment modality for patients with end-stage liver disease. With advances in surgical techniques, organ preservation, and immunosuppressant therapy, transplantation outcomes have continued to improve. 1 As life expectancy after LT has increased, metabolic complications such as dyslipidemia and new-onset diabetes after transplantation (NODAT) have also been on the rise. 2 Thus, it has become exceedingly important to prevent and/or manage these metabolic complications because they can negatively affect both graft and patient survival. NODAT in patients with liver allografts is significantly associated with hepatic artery thrombosis as well as acute and chronic rejection. 3,4 In addition, morbidity and mortality are greater in patients with NODAT. 5,6 It has been shown that the diabetogenic effects of immunosuppressants play a major role in the development of NODAT. 7,8 Current immunosuppressant regimens used in this population include steroids, calcineurin inhibitors (cyclosporine and tacrolimus), and sirolimus. Other variables, including genetic factors, 9,10 older age, 11,12 a high body mass index (BMI), 13 the presence of hepatitis C virus, 11 and impaired fasting glucose (IFG), 14 are also associated with NODAT development. 15 Notably, NODAT is a major independent risk factor for cardiovascular morbidity and mortality as well as graft loss. 16 Although dyslipidemia is uncommon in patients with liver cirrhosis, it is often observed in LT patients. 17,18 Statins (3-hydroxy-methylglutaryl coenzyme A reductase inhibitors) are widely used for the treatment of dyslipidemia in the general population and are considered to be first-line treatments for LT recipients to prevent cardiovascular disease by lowering serum low-density lipoprotein cholesterol levels. 19 However, several recent meta-analyses have revealed that statin therapy increases the risk of new-onset diabetes mellitus. 20 Few studies on the diabetogenic effects of statins in transplant patients have been reported. The aim of this study was to investigate the association between statin therapy and NODAT development in LT recipients. PATIENTS AND METHODS Subjects We conducted a retrospective, longitudinal, observational study of patients who underwent LT between January 1, 2005 and May 31, 2012 at Severance Hospital (Seoul, Korea) or Asan Medical Center (Seoul, Korea). Recipients between the ages of 20 and 75 years who survived for longer than 12 months after transplantation were included in this study. All patients with a history of diabetes mellitus or diabetes medication use before transplantation were excluded. All patients on statins at the time of LT were also excluded. Clinical data, including height, weight, and BMI, were measured, and the prevalence of hypertension and viral hepatitis was evaluated at the baseline. Fasting plasma glucose (FPG) levels and lipid profiles were also measured at the baseline (before transplantation) and 6, 12, 24, and 36 months after transplantation. BMI was also measured 12, 24, and 36 months after transplantation. From these data, we evaluated the incidence of NODAT according to statin use and other associated risk factors. Transient hyperglycemia after transplantation that was resolved within 6 months without treatment 21 was frequently observed, and these patients were not included in the NODAT group. The endpoint of this study was the development of NODAT 6 months or more after transplant surgery. NODAT was defined as an FPG level 126 mg/dl on 2 consecutive measurements, a hemoglobin A1c value 6.5%, or the use of glucose-lowering medications according to the 2003 international consensus guidelines. 22 Patients with FPG levels between 100 and 125 mg/dl were classified as having IFG. The study protocol was approved by the ethics committee of the Yonsei University College of Medicine. Statistical Analysis All statistical analyses were performed with the SPSS statistical analysis program (SPSS System for Windows 20.0, SPSS, Inc., Chicago, IL). All values are expressed as means and standard deviations or numbers and percentages. The normality of the distribution of continuous variables was examined with Shapiro-Wilk tests. Between-group differences of mean values were compared with unpaired t tests, and between-group differences of numbers and percentages were compared with v 2 tests. Any variable with a P value < 0.05 in the univariate analysis was included in the final multivariate model. Kaplan-Meier survival curves were used to compare disease-free survival. Multivariate Cox regression was performed with adjustments for significant predictors in the univariate analysis as well as other factors previously shown to be associated with the development of NODAT. For all statistical tests, a P value < 0.05 was considered to be statistically significant.
3 LIVER TRANSPLANTATION, Vol. 20, No. 5, 2014 CHO ET AL. 559 TABLE 1. Baseline Clinical Characteristics of the Patients Control Group (n 5 323) Statin Group (n 5 41) P Value Male sex [n (%)] 229 (70.9) 22 (53.7) 0.03 Hepatitis B [n (%)] 239 (74.0) 30 (73.2) 0.91 Hepatitis C [n (%)] 13 (4.0) 1 (2.4) 0.62 IFG before LT [n (%)] 109 (33.7) 9 (22.0) 0.13 Hypertension [n (%)] 56 (17.3) 14 (34.1) 0.01 BMI (kg/m 2 ) Changes in BMI (kg/m 2 ) From 0 to 1 year after LT From 1 to 2 years after LT From 2 to 3 years after LT From baseline to endpoint Obesity: BMI 25 kg/m 2 [n (%)] 119 (36.8) 14 (34.1) 0.74 Age (years) Treatment with tacrolimus [n (%)] 305 (94.4) 41 (100.0) 0.12 FPG before transplantation (mg/dl) Total cholesterol before LT (mg/dl) Change in total cholesterol from baseline to endpoint (mg/dl) Cumulative dose of steroids over course of 6 months (mg) Duration of follow-up (months) Donor type: living/cadaver (n/n) 264/59 29/ Acute rejection [n (%)] 46 (14.2) 9 (22.0) 0.39 NODAT development [n (%)] 57 (17.6) 13 (31.7) 0.03 NOTE: Values are presented as means and standard deviations unless otherwise noted. Differences between groups were analyzed with chi-square tests or unpaired t tests. Cumulative doses of steroids are equivalents of prednisone. Bolded values are significant. RESULTS Clinical Characteristics of the Study Population and NODAT Development Three hundred sixty-four LT recipients who underwent surgery between the ages of 20 and 75 years without a previous history of diabetes were enrolled in this study. One hundred fifty-four of these patients underwent LT at Severance Hospital, and 210 patients underwent LT at Asan Hospital. Three hundred fifty-four subjects were followed for at least 12 months after surgery, and 251 recipients were followed for at least 48 months. Forty-one recipients started on statins before the diagnosis of NODAT and used them for more than 6 months after LT. Twentyone patients were treated with atorvastatin, 8 were treated with fluvastatin, 6 were treated with pravastatin, 4 were treated with pitavastatin, and 2 were treated with rosuvastatin. The primary reason for starting statin therapy was hypercholesterolemia, and the mean total cholesterol level before statin use was mg/dl. None of the patients in the statin group had been diagnosed with NODAT before they started statin therapy. NODAT developed in 13 of the 41 statin users. The mean overall follow-up period was months. The control group was followed longer than the statin group, although this difference was not statistically significant ( versus months, P ; Table 1). The proportion of men was higher in the control group versus the statin group (70.9% versus 53.7%, P ; Table 1). There were no differences in the baseline BMI values or BMI changes (0, 1, 2, and 3 years after transplantation) between the 2 groups (Table 1). The prevalence of hypertension was higher in the statin group versus the control group (34.1% versus 17.3%, P ), as was the total cholesterol level before LT ( versus mg/dl, P ). There were no significant differences in age, BMI, prevalence of obesity, cumulative corticosteroid dose, prevalence of hepatitis C, donor type, incidence of acute rejection, or FPG levels between the groups (Table 1). The mean duration of statin use before NODAT development was 10.4 months. There was no significant difference in the mean statin treatment duration between the NODAT group and the no-nodat group (24.5 versus 21.5 months, P ). In addition, there was no difference in the dose of atorvastatin between the NODAT group and the no-nodat group (Supporting Table 1). Effects of Statin Treatment on Metabolic Parameters The mean fasting blood glucose and total cholesterol levels were significantly higher in the statin group versus the control group 6 to 12 months after LT.
4 560 CHO ET AL. LIVER TRANSPLANTATION, May 2014 Although total cholesterol levels were higher for the statin treatment group versus the control group, there were no significant differences in the total cholesterol levels between the 2 groups after statin treatment (Fig. 1). The incidence of NODAT was significantly higher in the statin group versus the control group (31.7% versus 17.6%, P ; Table 1). Independent Predictors of NODAT Development in LT Patients The use of statins [hazard ratio (HR) , 95% confidence interval (CI) , P ] and IFG before transplantation (HR , 95% CI , Figure 1. Changes in the mean total cholesterol level after LT. *P < 0.05 versus the control group. P ) showed significant associations with NODAT development after adjustments for other confounding factors (Table 2). Male sex, age, changes in BMI, hypertension, and hepatitis C did not significantly increase the risk of NODAT in the multivariate analysis (Table 2). According to the Cox regression analysis, statin use for longer than 6 months increased the risk of developing NODAT after LT after adjustments for age, sex, changes in BMI, hypertension, and IFG before transplantation (Fig. 2). Clinical Characteristics of NODAT Patients With Statin Treatment Patients who developed NODAT showed higher FPG levels at the baseline (before transplantation) than those who did not develop NODAT ( versus mg/dl, P ; Table 3). In addition, hypertension was more common in subjects with NODAT versus patients without NODAT (61.5% versus 25.0%, P ; Table 3). DISCUSSION Our study showed that the incidence of NODAT was significantly higher for patients who used statins after LT (31.7%) versus those who did not (17.6%, P ). Statin use for longer than 6 months was the principal factor related to the development of NODAT after LT (HR , 95% CI , P ). A recent meta-analysis showed that statin therapy was associated with an increased risk of new-onset diabetes (HR , 95% CI ), 20 whereas another study revealed that high-dose statin therapy could increase the risk of developing diabetes in comparison with moderate-dose statin therapy. 23 TABLE 2. Independent Predictors of NODAT Development in LT Patients Univariate Analysis Multivariate Analysis HR (95% CI) P Value HR (95% CI) P Value Use of statins 1.83 ( ) ( ) 0.01 Male sex 1.31 ( ) ( ) 0.17 Age (years) 1.03 ( ) ( ) 0.07 IFG before LT 2.11 ( ) < ( ) <0.01 Hypertension 0.96 ( ) ( ) 0.30 BMI (kg/m 2 ) 1.01 ( ) 0.80 Change in BMI from baseline to 1.01 ( ) ( ) 0.39 endpoint (kg/m 2 ) Hepatitis B 1.10 ( ) 0.73 Hepatitis C 1.68 ( ) ( ) 0.40 FPG before LT (mg/dl) 1.03 ( ) <20.01 Total cholesterol before LT (mg/dl) 1.00 ( ) 0.12 Change in total cholesterol from 1.00 ( ) 0.13 baseline to endpoint (mg/dl) Acute rejection after LT 1.33 ( ) 0.33 Cumulative dose of steroids over course of 6 months (mg) 1.00 ( ) 0.47 NOTE: Bolded values are significant.
5 LIVER TRANSPLANTATION, Vol. 20, No. 5, 2014 CHO ET AL. 561 Additionally, it has been shown that some populations, including the elderly, women, and Asians, are more vulnerable to developing diabetes. 24 There are few studies, however, that have examined the effects of statin use on the development of diabetes in liver allograft recipients. The prevalence of diabetes in LT recipients has been reported to vary between 2.5% and 25% because of differences in the criteria for Figure 2. Analysis of NODAT development according to the use of statins. Kaplan-Meier curves for NODAT development are shown. Adjustments have been made for age, sex, BMI changes, the prevalence of hypertension, and hepatitis C. diagnosis. 25 Morbidity was found to be significantly higher for patients who developed NODAT versus an age- and sex-matched group of patients without NODAT. 4 Also, NODAT has been reported to be a significant risk factor for liver-related death after transplantation. 26 Risk factors for NODAT, including pretransplant hyperglycemia (IFG), a higher BMI, an older age at the time of transplantation, higher steroid dose, genetic factors, and the type of immunosuppressant administered, have been widely studied. 9,11-15,19,27-29 Our study has similarly confirmed that IFG is a strong risk factor for the development of NODAT in patients who have undergone LT (HR , 95% CI , P < 0.01). Other investigators also reported that IFG before LT was a risk factor for NODAT development (odds ratio 5 3.8, 95% CI , P < 0.01) in a cohort of 211 LT recipients. 13 Pretransplant IFG in renal transplant patients has been associated with a higher incidence of NODAT, 30 as has an older age at the time of transplantation. Although statistically insignificant in this study, an older age at the time of LT tended to increase the risk of NODAT (HR , 95% CI , P ). We did not observe a significant association between pretransplant BMI and NODAT. It is thought that weight gain after transplantation may be a more important risk factor for NODAT than the baseline BMI, and because of ascites and peripheral edema before LT, BMI may have to be calculated according to the dry weight. 31 Hepatitis C TABLE 3. Clinical Characteristics of Patients Undergoing Statin Treatment According to NODAT Development No NODAT (n 5 28) NODAT (n 5 13) P Value Duration of statin treatment (months) Follow-up duration (months) Baseline BMI (kg/m 2 ) BMI 1 year after LT (kg/m 2 ) Change in BMI from 0 to 1 year after LT (kg/m 2 ) BMI 2 years after LT (kg/m 2 ) Change in BMI from 1 to 2 years after LT (kg/m 2 ) BMI 3 years after LT (kg/m 2 ) Change in BMI from 2 to 3 years after LT Change in BMI from baseline to endpoint (kg/m 2 ) Age at LT (years) Male sex [n (%)] 13 (46.4) 9 (69.2) 0.17 Cumulative dose of steroids over course of 6 months (mg) FPG before LT (mg/dl) FPG at the start of statin treatment (mg/dl) Total cholesterol before LT (mg/dl) Total cholesterol at the start of statin treatment (mg/dl) Total cholesterol 3 years after LT (mg/dl) Change in total cholesterol from baseline to 3 years after LT (mg/dl) Donor type: living/cadaver (n/n) 20/8 9/ Acute rejection [n (%)] 5 (17.9) 4 (30.8) 0.35 Hepatitis B [n (%)] 22 (78.6) 9 (69.2) 0.52 Hepatitis C [n (%)] 1 (3.6) 0 (0) 0.49 Hypertension [n (%)] 7 (25.0) 8 (61.5) 0.02 NOTE: Values are presented as means and standard deviations unless otherwise noted. Bolded values are significant.
6 562 CHO ET AL. LIVER TRANSPLANTATION, May 2014 infection is another important risk factor for NODAT. 25 Because only 3.8% of our enrolled patients had evidence of a hepatitis C viral infection, we did not observe an association in this study. The cumulative steroid dose within the first year after LT has been reported to increase the risk of NODAT development (odds ratio , 95% CI , P ), 8 although this was not observed in this study. Low maintenance steroid dosages may have contributed to this observation. To date, the precise pathophysiological mechanism underlying the diabetogenic effects of statins is poorly understood. Some studies have reported that impaired insulin secretion due to disrupted voltagegated calcium channel function in pancreatic b cells, 32 the disruption of mitochondrial function in pancreatic b cells, 33 myocytes, 34 and adipocytes, 35 statin-induced sarcopenia, 36 and muscle destruction 37,38 may play a role in the hyperglycemic effects of statins. Because transplant patients must take immunosuppressants for the duration of their life, drug interactions are an important concern. Cyclosporine is metabolized by cytochrome P450 3A4, and most statins (with the exception of pravastatin and fluvastatin) are also metabolized by cytochrome P450 3A4. Cyclosporine blood levels are slightly elevated with statin coadministration, whereas statin levels are increased several-fold. 39 Tacrolimus, on the other hand, does not increase statin levels to the same degree as cyclosporine. 40 It is possible that cyclosporine inhibits the metabolism of statins and thereby enhances statin toxicity. As a result, statin toxicity may be more obviously present in LT recipients. The cardiovascular and mortality benefits of using statins have been reported to exceed the diabetes risk, and this includes subjects at high risk of developing diabetes. 41 This would also apply to LT recipients. For this reason, a restriction of statins could be inappropriate for LT patients with hypercholesterolemia. In our opinion, statins should be used in LT patients with caution; cessation is not necessary. We performed additional analyses to assess differences in subject characteristics based on the presence of NODAT. Subjects who developed NODAT showed higher FPG levels at the baseline (P ), and a greater proportion of the patients had hypertension (P ). These findings indicate that patients with existing abnormalities of cardiometabolic components (eg, dysglycemia and hypertension) might be susceptible to the development of NODAT after statin treatment. In agreement with our results, a recent analysis from the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial 41 demonstrated that participants with 1 or more major diabetes risk factor had an increased risk of developing diabetes during the statin trial follow-up (incidence rate: 1.88 versus 0.18 per 100 person-years, HR , 95% CI , P ). Our study has several limitations. First, this was not a randomized, blinded, placebo-controlled, prospective clinical trial. Therefore, we could not prove a causal relationship between statin use and NODAT development. Additionally, we could not perform oral glucose tolerance tests in all patients before transplantation. Therefore, preexisting diabetes or impaired glucose tolerance without IFG could have led to an overestimation of NODAT. The sample size was too small to draw a clear causal relationship and investigate other possible interactions. However, our study benefits from long-term observation (the mean followup period was months after transplantation). Lastly, we could not analyze which statins are more or less diabetogenic because of the relatively small number of statins used in our patient population. However, our study is the first to confirm statin use as a risk factor for NODAT development in liver allograft recipients. In conclusion, chronic statin treatment for longer than 6 months could contribute to the development of NODAT in LT recipients, especially if they have higher baseline FPG levels. Patients with high baseline FPG levels are more likely to develop NODAT when they are placed on statin treatment after LT. Although statins are a cornerstone of modern cardiovascular medicine with benefits that clearly outweigh the risk of diabetes, physicians should monitor LT patients for diabetes when statins are used for the treatment of dyslipidemia. REFERENCES 1. Lee SG, Park KM, Hwang S, Lee YJ, Kim KH, Ahn CS, et al. Adult-to-adult living donor liver transplantation at the Asan Medical Center, Korea. Asian J Surg 2002;25: Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007;13: Colle I, Van Vlierberghe H, Troisi R, De Hemptinne B. Transplanted liver: consequences of denervation for liver functions. Anat Rec A Discov Mol Cell Evol Biol 2004; 280: John PR, Thuluvath PJ. Outcome of patients with newonset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 2002;8: Yoo HY, Thuluvath PJ. The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation. Transplantation 2002;74: Moon JI, Barbeito R, Faradji RN, Gaynor JJ, Tzakis AG. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: long-term follow up. Transplantation 2006;82: Kuo HT, Sampaio MS, Ye X, Reddy P, Martin P, Bunnapradist S. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. Transplantation 2010;89: Oufroukhi L, Kamar N, Muscari F, Lavayssière L, Guitard J, Ribes D, et al. Predictive factors for posttransplant diabetes mellitus within one-year of liver transplantation. Transplantation 2008;85: Kang ES, Kim MS, Kim CH, Nam CM, Han SJ, Hur KY, et al. Association of common type 2 diabetes risk gene
7 LIVER TRANSPLANTATION, Vol. 20, No. 5, 2014 CHO ET AL. 563 variants and posttransplantation diabetes mellitus in renal allograft recipients in Korea. Transplantation 2009; 88: Lee HC. Post-renal transplant diabetes mellitus in Korean subjects: superimposition of transplant-related immunosuppressant factors on genetic and type 2 diabetic risk factors. Diabetes Metab J 2012;36: Khalili M, Lim JW, Bass N, Ascher NL, Roberts JP, Terrault NA. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 2004;10: Mirabella S, Brunati A, Ricchiuti A, Pierini A, Franchello A, Salizzoni M. New-onset diabetes after liver transplantation. Transplant Proc 2005;37: Saliba F, Lakehal M, Pageaux GP, Roche B, Vanlemmens C, Duvoux C, et al.; for Diapason Study Group. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study. Liver Transpl 2007;13: Hur KY, Kim MS, Kim YS, Kang ES, Nam JH, Kim SH, et al. Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. Diabetes Care 2007;30: Sarno G, Mehta RJ, Guardado-Mendoza R, Jimenez-Ceja LM, De Rosa P, Muscogiuri G. New-onset diabetes mellitus: predictive factors and impact on the outcome of patients undergoing liver transplantation. Curr Diabetes Rev 2013;9: Pham PT, Pham PC, Lipshutz GS, Wilkinson AH. New onset diabetes mellitus after solid organ transplantation. Endocrinol Metab Clin North Am 2007;36: Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008;14: Reuben A. Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity. Liver Transpl 2001;7(suppl 1):S13-S Gotto AM Jr, Moon JE. Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol 2012;110(suppl):3A-14A. 20. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375: Arner P, Gunnarsson R, Blomdahl S, Groth CG. Some characteristics of steroid diabetes: a study in renaltransplant recipients receiving high-dose corticosteroid therapy. Diabetes Care 1983;6: Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernandez D, et al.; for International Expert Panel. Newonset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February Transplantation 2003;75(suppl):SS3-SS Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305: Goldstein MR, Mascitelli L. Do statins cause diabetes? Curr Diab Rep 2013;13: Baid S, Cosimi AB, Farrell ML, Schoenfeld DA, Feng S, Chung RT, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001;72: Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010;10: Parekh J, Corley DA, Feng S. Diabetes, hypertension and hyperlipidemia: prevalence over time and impact on long-term survival after liver transplantation. Am J Transplant 2012;12: Kang ES, Kim MS, Kim YS, Hur KY, Han SJ, Nam CM, et al. A variant of the transcription factor 7-like 2 (TCF7L2) gene and the risk of posttransplantation diabetes mellitus in renal allograft recipients. Diabetes Care 2008;31: Kang ES, Kim MS, Kim YS, Kim CH, Han SJ, Chun SW, et al. A polymorphism in the zinc transporter gene SLC30A8 confers resistance against posttransplantation diabetes mellitus in renal allograft recipients. Diabetes 2008;57: Cosio FG, Kudva Y, van der Velde M, Larson TS, Textor SC, Griffin MD, Stegall MD. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005;67: Everhart JE, Lombardero M, Lake JR, Wiesner RH, Zetterman RK, Hoofnagle JH. Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transpl Surg 1998;4: Xia F, Xie L, Mihic A, Gao X, Chen Y, Gaisano HY, Tsushima RG. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic b-cells. Endocrinology 2008;149: Mulder H, Ling C. Mitochondrial dysfunction in pancreatic b-cells in type 2 diabetes. Mol Cell Endocrinol 2009; 297: Kwak HB, Thalacker-Mercer A, Anderson EJ, Lin CT, Kane DA, Lee NS, et al. Simvastatin impairs ADPstimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radic Biol Med 2012;52: Kusminski CM, Scherer PE. Mitochondrial dysfunction in white adipose tissue. Trends Endocrinol Metab 2012;23: Khamseh ME, Malek M, Aghili R, Emami Z. Sarcopenia and diabetes: pathogenesis and consequences. Br J Diabetes Vasc Dis 2011;11: Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, Babiychuk EB. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006;210: Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med 2012;172: Asberg A, Hartmann A, Fjeldså E, Bergan S, Holdaas H. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant 2001;1: Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, Maes BD. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 2005;5: Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380:
Research Article New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database
Transplantation Volume 2013, Article ID 269096, 7 pages http://dx.doi.org/10.1155/2013/269096 Research Article New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients:
More informationWaist Circumference as an Independent Risk Factor for NODAT
ORIGINAL PAPER ISSN 1425-9524 DOI: 10.12659/AOT.892067 Received: 2014.07.23 Accepted: 2014.10.21 Published: 2015.03.20 Waist Circumference as an Independent Risk Factor for Authors Contribution: Study
More informationDiabetes, Hypertension and Hyperlipidemia: Prevalence Over Time and Impact on Long-Term Survival After Liver Transplantation
American Journal of Transplantation 2012; 12: 2181 2187 Wiley Periodicals Inc. C Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/j.1600-6143.2012.04077.x
More informationRisk of Diabetes in Patients Treated with HMG-CoA Reductase Inhibitors
Risk of Diabetes in Patients Treated with HMG-CoA Reductase Inhibitors Yongin Cho Department of Medicine The Graduate School, Yonsei University Risk of Diabetes in Patients Treated with HMG-CoA Reductase
More informationORIGINAL ARTICLE. Hung-Tien Kuo, 1,2 Erik Lum, 1 Paul Martin, 3 and Suphamai Bunnapradist ORIGINAL ARTICLE
ORIGINAL ARTICLE Effect of Diabetes and Acute Rejection on Liver Transplant Outcomes: An Analysis of the Organ rocurement and Transplantation Network/United Network for Organ Sharing Database Hung-Tien
More informationIncidence and Predictors of Stent Thrombosis after Percutaneous Coronary Intervention in Acute Myocardial Infarction
Incidence and Predictors of Stent Thrombosis after Percutaneous Coronary Intervention in Acute Myocardial Infarction Sungmin Lim, Yoon Seok Koh, Hee Yeol Kim, Ik Jun Choi, Eun Ho Choo, Jin Jin Kim, Mineok
More informationREACH Risk Evaluation to Achieve Cardiovascular Health
Dyslipidemia and transplantation History: An 8-year-old boy presented with generalized edema and hypertension. A renal biopsy confirmed a diagnosis of focal segmental glomerulosclerosis (FSGS). After his
More informationSERUM CYSTATIN C CONCENTRATION IS A POWERFUL PROGNOSTIC INDICATOR IN PATIENTS WITH CIRRHOTIC ASCITES
SERUM CYSTATIN C CONCENTRATION IS A POWERFUL PROGNOSTIC INDICATOR IN PATIENTS WITH CIRRHOTIC ASCITES YEON SEOK SEO, 1 SOO YOUNG PARK, 2 MOON YOUNG KIM, 3 SANG GYUNE KIM, 4 JUN YONG PARK, 5 HYUNG JOON YIM,
More informationStatin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography
Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,
More informationPretransplant Risk Factors for New-Onset Diabetes Mellitus After Transplant in Pediatric Liver Transplant Recipients
LIVER TRANSPLANTATION 16:1249-1256, 2010 ORIGINAL ARTICLE Pretransplant Risk Factors for New-Onset Diabetes Mellitus After Transplant in Pediatric Liver Transplant Recipients Hung-Tien Kuo, 1,2 Christine
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationPediatric Liver Transplantation Outcomes in Korea
ORIGINAL ARTICLE Cell Therapy & Organ Transplantation http://dx.doi.org/6/jkms.8..4 J Korean Med Sci 0; 8: 4-47 Pediatric Liver Transplantation Outcomes in Korea Jong Man Kim,, * Kyung Mo Kim,, * Nam-Joon
More informationRisk factors for new-onset diabetes mellitus after kidney transplantation (NODAT): a Brazilian single center study
original article Risk factors for new-onset diabetes mellitus after kidney transplantation (NODAT): a Brazilian single center study Camila Lima 1, Amanda Grden 1, Thelma Skare 1, Paulo Jaworski 1, Renato
More informationAssociation between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese
Diabetes Care Publish Ahead of Print, published online June 12, 2008 Raised Blood Pressure and Dysglycemia Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese Bernard My Cheung,
More informationA comparison of statistical methods for adjusting the treatment effects in genetic association studies of quantitative traits
34 1 Journal of the Korean Society of Health Information and Health Statistics Volume 34, Number 1, 2009, pp. 53 62 53 한경화 1), 임길섭 2), 박성하 3), 장양수 4), 송기준 2) 1), 2), 3), 4) A comparison of statistical
More informationOptimal Duration of Clopidogrel Therapy with DES to Reduce Late Coronary Arterial Thrombotic Event. The DES LATE Trial
Optimal Duration of Clopidogrel Therapy with DES to Reduce Late Coronary Arterial Thrombotic Event The DES LATE Trial Cheol Whan Lee, MD, Seung-Jung Park, MD, PhD, On Behalf of the DES LATE Investigators
More informationStatins and New Onset Diabetes Mellitus NPO
Learning Objectives 1) Recognize the risk of diabetes associated with statin therapy in a population at high risk for diabetes 2) Compare and contrast statin benefit to risk when treating patients in a
More informationThe Epidemiology of Diabetes in Korea
Review http://dx.doi.org/10.4093/dmj.2011.35.4.303 pissn 2233-6079 eissn 2233-6087 D I A B E T E S & M E T A B O L I S M J O U R N A L The Epidemiology of Diabetes in Korea Dae Jung Kim Department of Endocrinology
More informationThe role of glycated hemoglobin in the screening and diagnosis of renal posttransplantation diabetes
Federal University of Rio Grande do Sul Graduate Program in Endocrinology Brazil The role of glycated hemoglobin in the screening and diagnosis of renal posttransplantation diabetes Ana Laura Pimentel
More informationSeung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine
Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine The Scope of Optimal BP BP Reduction CV outcomes & mortality CKD progression - Albuminuria - egfr decline
More informationSteroid Minimization: Great Idea or Silly Move?
Steroid Minimization: Great Idea or Silly Move? Disclosures I have financial relationship(s) within the last 12 months relevant to my presentation with: Astellas Grants ** Bristol Myers Squibb Grants,
More informationORIGINAL ARTICLE. Eric F. Martin, 1 Jonathan Huang, 3 Qun Xiang, 2 John P. Klein, 2 Jasmohan Bajaj, 4 and Kia Saeian 1
LIVER TRANSPLANTATION 18:914 929, 2012 ORIGINAL ARTICLE Recipient Survival and Graft Survival are Not Diminished by Simultaneous Liver-Kidney Transplantation: An Analysis of the United Network for Organ
More informationCardiovascular Risk Reduction in Kidney Transplant Recipients
Cardiovascular Risk Reduction in Kidney Transplant Recipients Rainer Oberbauer R.O. AUG 2010 CV Mortality in ESRD compared to the general population R.O.2/32 Modified from Foley et al. AJKD 32 (suppl3):
More informationLong-term prognosis of BK virus-associated nephropathy in kidney transplant recipients
Original Article Kidney Res Clin Pract 37:167-173, 2018(2) pissn: 2211-9132 eissn: 2211-9140 https://doi.org/10.23876/j.krcp.2018.37.2.167 KIDNEY RESEARCH AND CLINICAL PRACTICE Long-term prognosis of BK
More informationStatin intolerance. Pr Franck Boccara, MD, PhD Cardiologie, INSERM UMRS938 CHU St Antoine, UPMC, Paris, France
Statin intolerance Pr Franck Boccara, MD, PhD Cardiologie, INSERM UMRS938 CHU St Antoine, UPMC, Paris, France Disclosure Statement of Financial Interest I currently have, or have had over the last two
More informationThe Diabetes Epidemic in Korea
Review Article Endocrinol Metab 2016;31:349-33 http://dx.doi.org/.3803/enm.2016.31.3.349 pissn 2093-96X eissn 2093-978 The Diabetes Epidemic in Korea Junghyun Noh Department of Internal Medicine, Inje
More informationYoung Seok Song 1, You-Cheol Hwang 2, Hong-Yup Ahn 3, Cheol-Young Park 1
Comparison of the Usefulness of the Updated Homeostasis Model Assessment (HOMA2) with the Original HOMA1 in the Prediction of Type 2 Diabetes Mellitus in Koreans Young Seok Song 1, You-Cheol Hwang 2, Hong-Yup
More informationChanges in the seroprevalence of IgG anti-hepatitis A virus between 2001 and 2013: experience at a single center in Korea
pissn 2287-2728 eissn 2287-285X Original Article Clinical and Molecular Hepatology 214;2:162-167 Changes in the seroprevalence of IgG anti-hepatitis A virus between 21 and 213: experience at a single center
More informationSupplementary Appendix
Supplementary Appendix Increased Risk of Atrial Fibrillation and Thromboembolism in Patients with Severe Psoriasis: a Nationwide Population-based Study Tae-Min Rhee, MD 1, Ji Hyun Lee, MD 2, Eue-Keun Choi,
More informationOriginal paper. Abstract. Abdullah S. Asia 1*, Al-Mahdi A. Modar 2, Hadi M. Ali 3
Original paper Frequency Of Potential Adverse Effects Of A Semisynthetic Statin (Simvastatin) Compared To A Synthetic Statin (Atorvastatin) Used To Reduce Cardiovascular Risk For Patients In Basra 1*,
More informationPancreas After Islet Transplantation: A First Report of the International Pancreas Transplant Registry
American Journal of Transplantation 2016; 16: 688 693 Wiley Periodicals Inc. Brief Communication Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons doi:
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationLong term liver transplant management
Long term liver transplant management Dr Bill Griffiths Cambridge Liver Unit Royal College of Physicians 5.7.17 Success of Liver Transplantation Current survival, 1 st elective transplant: 1 yr survival
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationCardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy
Journal of the American College of Cardiology Vol. 61, No. 2, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.042
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationSeung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC. Cardiovascular Center, Korea University Guro Hospital
Novel Statin Strategy to Prevent Atherosclerotic Cardiovascular Disease in Diabetic Patients-Curtailing Heart Attack : Korean Data and JUPITER again in spotlight Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI,
More informationHeart Rate and Cardiac Allograft Vasculopathy in Heart Transplant Recipients
ESC Congress 2011 Paris 27-31 August Heart Rate and Cardiac Allograft Vasculopathy in Heart Transplant Recipients M.T. La Rovere, F. Olmetti, G.D. Pinna, R. Maestri, D. Lilleri, A. D Armini, M. Viganò,
More informationLAMIS (Livalo in AMI Study)
JCR 2018. 12. 8 LAMIS (Livalo in AMI Study) Young Joon Hong Division of Cardiology, Chonnam National University Hospital Gwangju, Korea Trend of hypercholesterolemia in Korea < Prevalence of hypercholesterolemia
More informationEuropean Risk Management Plan. Measures impairment. Retreatment after Discontinuation
European Risk Management Plan Table 6.1.4-1: Safety Concern 55024.1 Summary of Risk Minimization Measures Routine Risk Minimization Measures Additional Risk Minimization Measures impairment. Retreatment
More informationHow to improve long term outcome after liver transplantation?
How to improve long term outcome after liver transplantation? François Durand Hepatology & Liver Intensive Care University Paris Diderot INSERM U1149 Hôpital Beaujon, Clichy PHC 2018 www.aphc.info Long
More informationManagement of Diabetes After Solid Organ Transplantation
Management of Diabetes After Solid Organ Transplantation Aidar R. Gosmanov, MD, PhD, FACE Chief, Endocrinology Section Stratton VAMC, Albany, NY Associate Professor of Medicine Division of Endocrinology,
More informationTreatment outcomes and survival based on drug resistance patterns in multidrug-resistant
Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis Doh Hyung Kim, Hee Jin Kim, Seung-Kyu Park, Suck-Jun Kong, Young Sam Kim, Tae-Hyung Kim, Eun Kyung
More informationAntithrombotic Therapy in Patients with Atrial Fibrillation
Antithrombotic Therapy in Patients with Atrial Fibrillation June Soo Kim, M.D., Ph.D. Department of Medicine Cardiac & Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine
More informationStandardized Thyroid Cancer Mortality in Korea between 1985 and 2010
Original Article Endocrinol Metab 2014;29:530-535 http://dx.doi.org/10.3803/enm.2014.29.4.530 pissn 2093-596X eissn 2093-5978 Standardized Thyroid Cancer Mortality in Korea between 1985 and 2010 Yun Mi
More informationExperience of Korea Acute Myocardial Infarction Registry (KAMIR)
Japan-Korea Joint AMI Symposium Korean Society of Myocardial Infarction Apr 18-19 2014 Experience of Korea Acute Myocardial Infarction Registry (KAMIR) Myung Ho Jeong, MD, PhD, FACC, FAHA, FESC, FSCAI,
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationORIGINAL ARTICLE Gastroenterology & Hepatology INTRODUCTION
ORIGINAL ARTICLE Gastroenterology & Hepatology http://dx.doi.org/10.3346/jkms.2013.28.8.1207 J Korean Med Sci 2013; 28: 1207-1212 The Model for End-Stage Liver Disease Score-Based System Predicts Short
More informationAnalysis of the outcome of young age tongue squamous cell carcinoma
Jeon et al. Maxillofacial Plastic and Reconstructive Surgery (2017) 39:41 DOI 10.1186/s40902-017-0139-8 Maxillofacial Plastic and Reconstructive Surgery RESEARCH Open Access Analysis of the outcome of
More informationOHSU Digital Commons. Oregon Health & Science University. Tysen June Cullen. Scholar Archive. September 2012
Oregon Health & Science University OHSU Digital Commons Scholar Archive September 2012 Body mass index and the development of newonset diabetes mellitus or the worsening of preexisting diabetes mellitus
More informationCURRICULUM VITAE July 5, Name Chang-Kwon Oh. Date of Birth August 15, 1961
CURRICULUM VITAE July 5, 2014 Name Chang-Kwon Oh Date of Birth August 15, 1961 Present Academic & Hospital Appointment Professor, Department of Surgery Ajou University, School of Medicine Chief, Department
More informationFemale, years or younger BMI of 30 or less at time of Diabetes diagnosis Prefer no family history of diabetes Took Lipitor consistently for at
Female, 51-70 years or younger BMI of 30 or less at time of Diabetes diagnosis Prefer no family history of diabetes Took Lipitor consistently for at least two months prior to diagnosis or within six months
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationPrevalence of Sarcopenia Adjusted Body Mass Index in the Korean Woman Based on the Korean National Health and Nutritional Examination Surveys
J Bone Metab 2016;23:243-247 https://doi.org/10.11005/jbm.2016.23.4.243 pissn 2287-6375 eissn 2287-7029 Original Article Prevalence of Sarcopenia Adjusted Body Mass Index in the Korean Woman Based on the
More informationStatins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.
More informationSerum uric acid levels improve prediction of incident Type 2 Diabetes in individuals with impaired fasting glucose: The Rancho Bernardo Study
Diabetes Care Publish Ahead of Print, published online June 9, 2009 Serum uric acid and incident DM2 Serum uric acid levels improve prediction of incident Type 2 Diabetes in individuals with impaired fasting
More informationSocioeconomic status risk factors for cardiovascular diseases by sex in Korean adults
, pp.44-49 http://dx.doi.org/10.14257/astl.2013 Socioeconomic status risk factors for cardiovascular diseases by sex in Korean adults Eun Sun So a, Myung Hee Lee 1 * a Assistant professor, College of Nursing,
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationNew-onset diabetes after transplantation. Christophe Legendre Université Paris Descartes & Hôpital Necker, Paris.
New-onset diabetes after transplantation Christophe Legendre Université Paris Descartes & Hôpital Necker, Paris. Actualités Jean Hamburger Paris, 23-24 avril 2012 NODAT IFG IGT CJ Yates et al, Am J Transplant
More informationEffect of donor-specific antibodies and panel reactive antibodies in living donor liver transplant recipients
ORIGINAL ARTICLE pissn 2288-6575 eissn 2288-6796 http://dx.doi.org/1.4174/astr.215.88.2.1 Annals of Surgical Treatment and Research Effect of donor-specific antibodies and panel reactive antibodies in
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationThe enteroinsular axis in the pathogenesis of prediabetes and diabetes in humans
The enteroinsular axis in the pathogenesis of prediabetes and diabetes in humans Young Min Cho, MD, PhD Division of Endocrinology and Metabolism Seoul National University College of Medicine Plasma glucose
More informationThe changes of subtypes in pediatric diabetes and their clinical and laboratory characteristics over the last 20 years
Original article http://dx.doi.org/10.6065/apem.2016.21.2.81 Ann Pediatr Endocrinol Metab 2016;21:81-85 The changes of subtypes in pediatric diabetes and their clinical and laboratory characteristics over
More informationDiagnostic Analysis of Patients with Essential Hypertension Using Association Rule Mining
Original Article Healthc Inform Res. 2010 June;16(2):77-81. pissn 2093-3681 eissn 2093-369X Diagnostic Analysis of Patients with Essential Hypertension Using Association Rule Mining A Mi Shin, RN, MS 1,
More informationSolid organ transplantation is currently an important
REVIEW Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes Vijay Shivaswamy, Brian Boerner, and Jennifer Larsen Division of Diabetes, Endocrinology, and Metabolism (V.S., B.B.,
More informationMetabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology
Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient
More informationRisk Factors for New-Onset Diabetes Mellitus Following Liver Transplantation and Impact of Hepatitis C Infection : An Observational Multicenter Study
LIVER TRANSPLANTATION 13:136-144, 2007 ORIGINAL ARTICLE Risk Factors for New-Onset Diabetes Mellitus Following Liver Transplantation and Impact of Hepatitis C Infection : An Observational Multicenter Study
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationSerum Cholesterol Changes in Long-Term Survivors of Liver Transplantation: A Comparison Between Cyclosporine and Tacrolimus Therapy
Serum Cholesterol Changes in Long-Term Survivors of Liver Transplantation: A Comparison Between Cyclosporine and Tacrolimus Therapy Ramón Charco,* Carme Cantarell, Victor Vargas,* Luis Capdevila, Jose
More informationRisk Factors for Ischemic Stroke: Electrocardiographic Findings
Original Articles 232 Risk Factors for Ischemic Stroke: Electrocardiographic Findings Elley H.H. Chiu 1,2, Teng-Yeow Tan 1,3, Ku-Chou Chang 1,3, and Chia-Wei Liou 1,3 Abstract- Background: Standard 12-lead
More informationOriginal Article INTRODUCTION. Korean Diabetes J 2010;34: doi: /kdj pissn eissn
Original Article doi: 10.4093/kdj.2010.34.6.359 pissn 1976-9180 eissn 2093-2650 A Retrospective Study on the Efficacy of a Ten- Milligram Dosage of Atorvastatin for Treatment of Hypercholesterolemia in
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationThe MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationClinical Outcomes of Renal Transplantation in Hepatitis C Virus Positive Recipients
Original Research Article Clinical Outcomes of Renal Transplantation in Hepatitis C Virus Positive Recipients Surendran Sujit 1*, N. Gopalakrishnan 2 1 Assistant Professor, 2 Professor and Head Department
More informationImpact of Angiotensin Converting Enzyme Inhibitor versus Angiotensin Receptor Blocker on Incidence of New-Onset Diabetes Mellitus in Asians
Original Article Yonsei Med J 2016 Jan;57(1):180-186 pissn: 0513-5796 eissn: 1976-2437 Impact of Angiotensin Converting Enzyme Inhibitor versus Angiotensin Receptor Blocker on Incidence of New-Onset Diabetes
More informationCigarette Smoking and Mortality in the Korean Multi-center Cancer Cohort (KMCC) Study
Journal of Preventive Medicine and Public Health March 2010, Vol. 43, No. 2, 151-158 doi: 10.3961/jpmph.2010.43.2.151 Cigarette Smoking and Mortality in the Korean Multi-center Cancer Cohort (KMCC) Study
More informationAn example of a systematic review and meta-analysis
An example of a systematic review and meta-analysis Sattar N et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742. Search strategy
More informationQuality ID #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Quality ID #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationQuality of life (QoL) in metastatic breast cancer patients with. maintenance paclitaxel plus gemcitabine (PG) chemotherapy:
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy
More informationOPEN. Yong-ho Lee
www.nature.com/scientificreports Received: 6 March 2018 Accepted: 30 July 2018 Published: xx xx xxxx OPEN Differential association of ezetimibe-simvastatin combination with major adverse cardiovascular
More informationOutcomes of living donor kidney transplantation in diabetic patients: age and sex matched comparison with non-diabetic patients
ORIGINAL ARTICLE Korean J Intern Med 2018;33:356-366 Outcomes of living donor kidney transplantation in diabetic patients: age and sex matched comparison with non-diabetic patients Chung Hee Baek 1, Hyosang
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationPeriodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice
Drugs R D (2014) 14:221 225 DOI 10.1007/s40268-014-0061-9 ORIGINAL RESEARCH ARTICLE Periodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice Theodore Christou Hesham R. Omar
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors
More informationRisk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment
pissn 1013-9087ㆍeISSN 2005-3894 Ann Dermatol Vol. 30, No. 2, 2018 https://doi.org/10.5021/ad.2018.30.2.143 ORIGINAL ARTICLE Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis
More informationWhy Do We Care About Prediabetes?
Why Do We Care About Prediabetes? Complications of Diabetes Diabetic Retinopathy Leading cause of blindness in adults 1,2 Diabetic Nephropathy Leading cause of Kidney failure Stroke 2- to 4-fold increase
More informationFactors Influencing Suicidal Ideation in the Elderly
, pp.43-47 http://dx.doi.org/10.14257/astl.2015.104.10 Factors Influencing Suicidal Ideation in the Elderly Byung Deog Hwang 1, Jae Woo Park 2, Ryoung Choi 3 1 Catholic University of Pusan, Department
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationRosuvastatin 5 mg, 10 mg and 20 mg Tablet
Rosuvastatin 5 mg, 10 mg and 20 mg Tablet Description is a preparation of Rosuvastatin. Rosuvastatin is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to
More informationObjectives. Kidney Complications With Diabetes. Case 10/21/2015
Objectives Kidney Complications With Diabetes Brian Boerner, MD Diabetes, Endocrinology, and Metabolism University of Nebraska Medical Center Review screening for, and management of, albuminuria Review
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationCurrent status of hepatic surgery in Korea
Korean J Hepatol. 2009 Dec; 15(Suppl 6):S60 - S64. DOI: 10.3350/kjhep.2009.15.S6.S60 Current status of hepatic surgery in Korea Kyung Sik Kim Department of Surgery, Severance Hospital, Yonsei University
More informationComparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients
Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 1Q18 January February
BRAND NAME Prevymis TM GENERIC NAME Letermovir MANUFACTURER Merck & Co., Inc. DATE OF APPROVAL November 9, 2017 PRODUCT LAUNCH DATE TBD REVIEW TYPE Review type 1 (RT1): New Drug Review Full review of new
More information